Videos

Graft versus Host Disease

David S. Snyder, MD, discusses using ruxolitinib to prevent patients receiving stem cell transplantation from developing graft versus host disease.

Sarah Ferguson, MD, FRCSC, discusses her experience being involved in a population-based study of women with cervical cancer treated with a radical hysterectomy.

Kim N. Chi, MD, discusses the safety findings for the next-generation androgen receptor inhibitor apalutamide in combination with androgen deprivation therapy in patients with metastatic castration-sensitive prostate cancer, according to findings from the phase III TITAN study. This combination was compared with placebo and ADT and presented at the 2019 ASCO Annual Meeting.

Aditya Bardia, MBBS, MPH, discusses the value of liquid biopsies in the treatment landscape of breast cancer. The real value of liquid biopsy in this space lies in providing oncologists with insight on what’s happening in tumor evolution.

Optimal Management of Relapsed/Refractory mHCC

Sagar Lonial, MD, discusses how phase III trials should be designed in the United States for patients with multiple myeloma in the early-relapse setting.

Jesus Anampa, MD, MS, assistant professor, Department of Medicine, Albert Einstein School of Medicine, says in the past, most patients with breast cancer were treated with chemotherapy. In some cases, these patients were being over-treated. To limit the use of chemotherapy in patients who don’t need it, a group of researchers conducted the TAILORx trial.

Keith T. Flaherty, MD, discusses the combination regimens and the potential role for a 3-drug regimen as treatment for patients with melanoma. He says investigators have been searching for new combination strategies beyond the combination of BRAF and MEK inhibitors.

Jorge E. Cortes, MD, discusses the frontline treatment options for patients with chronic myeloid leukemia.

Angela DeMichele, MD, MSCE, discusses predictors of response to neoadjuvant chemotherapy in various subgroups of patients with breast cancer. Selecting characteristics of patients who will most likely benefit from this therapy is not an exact science, she adds.

Sarah B. Goldberg, MD, MPH, discusses the role of clinical trials in patients with lung cancer who have molecularly altered tumors, such as&nbsp;<em>EGFR</em>,&nbsp;<em>ALK</em>,&nbsp;<em>BRAF</em>,<em>ROS1,&nbsp;</em>or other alterations. These patients typically consider either targeted therapy or immunotherapy treatment options.

Graft versus Host Disease

Naveen Pemmaraju, MD, discusses the current understandings of how myelofibrosis presents in patients.

Andrew Turk, MD, discusses targeted agents that are making a splash in the treatment landscape of thyroid cancers, including the most aggressive form of the disease, anaplastic thyroid carcinoma. He says targeted agents have already become well established in the space of thyroid cancers, but these agents continue to evolve.

Lowell L. Hart, MD, FACP, scientific director of clinical research, Florida Cancer Specialists & Research Institute, and associate professor of medicine, Wake Forest University School of Medicine, discusses the effect of CDK4/6 inhibitor, trilaciclib on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan. Hart presented the phase II results from the blinded, multicenter study during the 2019 ASCO Annual Meeting.

Heinz-Josef Lenz, MD, discusses the significance of the latest updates in the CheckMate 142 trial exploring an immunotherapy treatment combination in patients with metastatic colorectal cancer whose tumors are microsatellite instability&ndash;high or mismatch repair deficient.

Peter Martin, MD, discusses the differences between subgroups of mantle cell lymphoma. MCL is a heterogenous disease, and in the World Health Organization classification of lymphoid neoplasms, MCL has a leukemia non-nodal presentation, says Martin.